NARAC 2016 - Update In Rhinology & Allergy

St Thomas , VI US
January 14, 2016 to January 16, 2016

NARAC is an annual meeting dually representing Allergists and ENTs with the goal of improving the accuracy of diagnosis and effectiveness of treatments for allergic and rhinologic diseases

Target Audience

Practicing Allergists and Rhinologists, Fellows in Allergy and Rhinology training programs, Primary Care physicians who care for Allergy and Rhinology patients, Allied health professionals in the field of Allergy and Rhinology

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify appropriate strategies to determine the diagnosis of chronic rhinosinusitis and its subtypes.
  • Discuss the hypothesized pathophysiologic mechanisms for development of chronic rhinosinusitis.
  • Identify potential complications of sinonasal disease and develop strategies for their prevention.
  • Weigh the risks and benefits of novel medical and surgical therapeutic modalities for chronic rhinosinusitis. 
  • Develop optimal treatment strategies for moderate to severe allergic rhinitis.
  • Develop strategies to screen for and diagnose sleep disordered breathing related to nasal disease.
  • Diagnose and treate hereditary angioedema. 
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships to disclose must also inform the learners prior to the start of the activity. Individuals with no financial relationships to disclose must also inform the learners that no financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

Jonathan Bernstein, MD
Speaker: Shire, CSL Behring, Novartis/Genentech, Greer
Honorarium: Shire, CSL Behring, Novartis/Genentech, AstraZeneca, Greer
Consultant: Shire, Dyax, CSL Behring, Novartis/Genentech, AstraZeneca, Meda, Biocryst, Greer, Boehringer Ingelheim

Ben Bleier, MD
Consultant: Olympus, Arthrocare, Karl Storz
Stocks: Interscope

Larry Borish, MD
Consultant: Teva, Allakos, Knopp, Genentech/Novartis Data Safety Monitoring Board: Pluristem

Don Bukstein, MD
Speaker: AstraZeneca, Genentech, Meda, Merck, Novartis, Teva Circassia
Honorarium: AstraZeneca, Genentech, Meda, Merck, Novartis, Teva Circassia

Thomas Casale, MD
Consultant: AstraZeneca, Genentech, Novartis, Teva, Sanofi Regeneron, Boehringer Ingleheim, Circassia
Research: AstraZeneca, Genentech, Novartis, Teva, Sanofi Regeneron, Cytos

Rakesh Chandra, MD
Consultant: Johnson & Johnson, Olympus, Meda, Intersect
Research: Johnson & Johnson, Intersect
Honorarium: Johnson & Johnson, Olympus, Meda

Alexander G. Chiu, MD
Consultant: Olympus, Meda

Ray S. Davis, MD
Consultant: Teva, Merck, Meda, Mylan, AstraZeneca, Mylan & AANMA, Baxalta, Neohealth, Onyx & Noven & GNE
Speaker: Teva, Merck, Meda, Mylan, AstraZeneca, Mylan & AANMA
Honorarium: Teva, Merck, Meda, Mylan, AstraZeneca, Mylan & AANMA

David Hagaman, MD
Consultant: BreatheAmerica Speaker: Merck

Anju Peters, MD
Consultant: Baxter, Greer

Vijay Ramakrishnan, MD
Consultant: Acclarent, Medtronic Research: NeilMed

Raymond Sacks, MD
Consultant: Medtronic Speaker: Meda

Rodney Schlosser, MD
Consultant: Olympus, Meda Speaker: Entellus, IntersectENT

Russell Settipane, MD
Consultant: AstraZeneca, Teva, Merck
Speaker: Genentech, Mylan, Meda, Teva, Merck
Research Grant: Novartis, Genentech, Mylan, Oriel Therapeutics, Teva, Merck, Circassia
Employee/Stockholder: OceanSide Publications

Zachary M. Soler, MD
Consultant: Olympus

The Following have no financial relationships to disclose:
Tara Carr, MD Alan Gaines, MD Robert Kern, MD Ginny Loiselle Raj Sindwani, MD

Education Staff/Committee have no financial relationships to disclose, except as may be listed above.

Course summary
Available credit: 
  • 13.50 AMA PRA Category 1 Credit™
  • 13.50 Attendance
Course opens: 
01/14/2016
Course expires: 
01/16/2018
Event starts: 
01/14/2016 - 4:00pm
Event ends: 
01/16/2016 - 1:30pm
Cost:
$0.00
Rating: 
5
Marriott Frenchman's Reef & Morning Star St. Thomas VI
5 Estate Bakkeroe
St Thomas , VI 00801
United States

Available Credit

  • 13.50 AMA PRA Category 1 Credit™
  • 13.50 Attendance

Accreditation Period

Course opens: 
01/14/2016
Course expires: 
01/16/2018

Price

Cost:
$0.00
Please login or create an account to take this course.